Abstract
Metoclopramide, the only drug approved by the FDA for treatment of diabetic gastroparesis, but used off-label for a variety of other gastrointestinal indications, has many potentially troublesome adverse neurologic effects, particularly movement disorders. In this article, we comprehensively review the indications and side effects of metoclopramide, and describe some common pitfalls and strategies to minimize the medicolegal risks to the prescribing physician. Metoclopramide accounts for nearly a third of all drug-induced movement disorders, a common reason for a malpractice suit. The entire spectrum of drug-induced movement disorders, ranging from subtle to life-threatening, can ensue from its use; akathisia and dystonia are generally seen early in the course of metoclopramide-induced movement disorders, whereas tardive dyskinesia and parkinsonism seem to be more prevalent in chronic users. Female sex, age and diabetes are the major risk factors for metoclopramide-induced movement disorders. It is therefore incumbent on gastroenterologists and other prescribing physicians to become familiar with the adverse neurologic effects associated with the use of metoclopramide, and to take appropriate preventive and defensive measures.
Key Points
-
Patients most at risk of developing metoclopramide-induced movement disorders are women, the elderly, and diabetics
-
A method for screening for neurologic complications should be developed at baseline and follow-up visits
-
Patient-oriented literature on side effects should be provided and informed consent should be obtained before prescribing metoclopramide
-
The evidence for efficacy in a given patient should be periodically reviewed and complete discontinuation or drug 'holidays' considered
-
Doses of metoclopramide >10 mg 3–4 times daily should be avoided unless absolutely necessary
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tonini M et al. (2004) Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 19: 379–390
Shaffer D et al. (2004) Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc (Wash DC) 44: 661–665
Pasricha PJ (2005) Treatment of disorders of bowel motility and water flux; antiemetics; agents used in biliary and pancreatic disease. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, edn 11, 983 (Eds Brunton LL et al.) New York: McGraw-Hill
Gralla RJ et al. (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305: 905–909
Onsrud M et al. (1988) High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma. Cancer 61: 2429–2432
Warrington PS et al. (1986) Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. Br Med J (Clin Res Ed) 293: 1334–1337
Henzi I et al. (1999) Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies. Br J Anaesth 83: 761–771
Fujii Y et al. (2000) Randomized clinical trial of granisetron, droperidol and metoclopramide for the treatment of nausea and vomiting after laparoscopic cholecystectomy. Br J Surg 87: 285–288
McCallum RW et al. (1984) Metoclopramide in gastroesophageal reflux disease: rationale for its use and results of a double-blind trial. Am J Gastroenterol 79: 165–172
van Pinxteren B et al. (2000) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. The Cochrane Database of Systematic Reviews, Issue 4, Art No. CD002095
McCallum RW et al. (1975) Comparative effects of metoclopramide and bethanechol on lower esophageal sphincter pressure in reflux patients. Gastroenterology 68: 1114–1118
Durazo FA and Valenzuela JE (1993) Effect of single and repeated doses of metoclopramide on the mechanisms of gastroesophageal reflux. Am J Gastroenterol 88: 1657–1662
Craig WR et al. (2004) Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. The Cochrane Database of Systematic Reviews, Issue 4, Art No. CD003502
Talley NJ (2003) Diabetic gastropathy and prokinetics. Am J Gastroenterol 98: 264–271
Parkman HP et al. (2004) American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 127: 1592–1622
Sturm A et al. (1999) Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 60: 422–427
Whatley K et al. (1984) When does metoclopramide facilitate transpyloric intubation? JPEN J Parenter Enteral Nutr 8: 679–681
Silva CC et al. (2002) Metoclopramide for migration of naso-enteral tube. The Cochrane Database of Systematic Reviews, Issue 4, Art No.CD003353
Morewood DJ and Whitehouse GH (1986) A comparison of three methods for performing barium follow-through studies of the small intestine. Br J Radiol 59: 971–973
Thoeni R and Filson R (1988) Abdominal and pelvic CT: use of oral metoclopramide to enhance bowel opacification. Radiology 169: 391–393
Cheape JD et al. (1991) Does metoclopramide reduce the length of ileus after colorectal surgery? A prospective randomized trial. Dis Colon Rectum 34: 437–441
Tollesson PO et al. (1991) Lack of effect of metoclopramide on colonic motility after cholecystectomy. Eur J Surg 157: 355–358
Davidson ED et al. (1979) The effects of metoclopramide on postoperative ileus. A randomized double-blind study. Ann Surg 190: 27–30
Golub RW et al. (1995) Colonoscopic bowel preparations—which one? A blinded, prospective, randomized trial. Dis Colon Rectum 38: 594–599
Scharman EJ et al. (1994) Efficiency of whole bowel irrigation with and without metoclopramide pretreatment. Am J Emerg Med 12: 302–305
Brady CE III et al. (1985) Golytely lavage—is metoclopramide necessary? Am J Gastroenterol 80: 180–184
Battle WM et al. (1980) Colonic dysfunction in diabetes mellitus. Gastroenterology 79: 1217–1221
Battle WM et al. (1981) Abnormal colonic motility in progressive systemic sclerosis. Ann Intern Med 94: 749–752
Selby W (2005) Complete small-bowel transit in patients undergoing capsule endoscopy: determining factors and improvement with metoclopramide. Gastrointest Endosc 61: 80–85
Jankovic J (1995) Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 18: 197–214
Stewart RB et al. (1992) Metoclopramide: an analysis of inappropriate long-term use in the elderly. Ann Pharmacother 26: 977–979
Ganzini L et al. (1993) The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 153: 1469–1475
Ayd FJ Jr (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175: 1054–1060
Arana GW et al. (1988) Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 145: 993–996
Miller LG and Jankovic J (1990) Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J 83: 525–532
Jankovic J (1989) The relationship between Parkinson's disease and other movement disorders. In Handbook of Experimental Pharmacology, 227–270 (Ed. Calne DB) Berlin: Springer-Verlag. [Vol 88]
Hardie RJ and Lees AJ (1988) Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51: 850–854
Melamed E et al. (1991) Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuropharmacol 14: 273–278
Gimenez-Roldan S and Mateo D (1991) Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor. Clin Neuropharmacol 14: 156–164
Bocola V et al. (1996) Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs. J Neurol Neurosurg Psychiatry 60: 213–216
Rajput AH et al. (1982) Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol 39: 644–646
Drake RE and Ehrlich J (1985) Suicide attempts associated with akathisia. Am J Psychiatry 142: 499–501
Herrera JN et al. (1988) High potency neuroleptics and violence in schizophrenics. J Nerv Ment Dis 176: 558–561
Walters AS et al. (1991) Review and videotape recognition of idiopathic restless legs syndrome. Mov Disord 6: 105–110
Sachdev P and Loneragan C (1993) Intravenous benztropine and propranolol challenges in tardive akathisia. Psychopharmacology (Berl) 113: 119–122
Guyot MC et al. (1997) Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 81: 141–149
Kornhuber J and Weller M (1994) Neuroleptic malignant syndrome. Curr Opin Neurol 7: 353–357
Buckley PF and Hutchinson M (1995) Neuroleptic malignant syndrome. J Neurol Neurosurg Psychiatry 58: 271–273
Kane JM and Smith JM (1982) Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39: 473–481
Jankovic J (1994) Stereotypies. In Movement Disorders, 503–517 (Eds Marsden CA and Fahn S) London: Butterworth Scientific
Glazer WM et al. (1998) Heterogeneity of tardive dyskinesia. A multivariate analysis. Br J Psychiatry 152: 253–259
Stacy M et al. (1993) Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 43: 937–941
Walters AS et al. (1990) A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea. Clin Neuropharmacol 13: 236–240
Macpherson R and Collis R (1992) Tardive dyskinesia. Patients' lack of awareness of movement disorder. Br J Psychiatry 160: 110–112
Hunter C et al.: Medications associated with onset of tardive dyskinesia. Neurology, in press
Bateman DN et al. (1985) Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed) 291: 930–932
Miller LG and Jankovic J (1989) Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 149: 2486–2492
Schroeder JA et al. (1994) The effect of intravenous ranitidine and metoclopramide on behavior, cognitive function, and affect. Anesth Analg 78: 359–364
Sewell DD et al. (1994) Metoclopramide and tardive dyskinesia. Biol Psychiatry 36: 630–632
Avorn J et al. (1995) Increased incidence of levodopa therapy following metoclopramide use. JAMA 274: 1780–1782
Jeste DV et al. (1988) Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 8 (Suppl 4): S38–S48
Klawans HL et al. (1984)The reversibility of “permanent” tardive dyskinesia. Clin Neuropharmacol 7: 153–159
Jankovic J and Beach J (1997) Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48: 359–362
Paleacu D et al. (2004) Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 27: 230–233
Lieberman JA et al. (1989) Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. Arch Gen Psychiatry 46: 908–913
Anderson EP and Freeman EB (2004) Recognition of movement disorders: extrapyramidal side effects and tardive dyskinesia.Would you recognize them if you see them? Pract Gastroenterol 28: 14–26
Kaye NS and Reed TJ (1999) Tardive dyskinesia: tremors in law and medicine. J Am Acad Psychiatry Law 27: 315–333
Hasler WL (2003) Pharmacotherapy for intestinal motor and sensory disorders. Gastroenterol Clin North Am 32: 707–732
Bianchi C et al. (1970) Effects of metoclopramide on isolated guinea-pig colon. 2. Interference with ganglionic stimulant drugs. Eur J Pharmacol 12: 332–341
Beani L et al. (1970) Effects of metoclopramide on isolated guinea-pig colon. 1. Peripheral sensitization to acetylcholine. Eur J Pharmacol 12: 320–331
Meshkinpour H et al. (1981) Electrical control activity in the sigmoid colon: effect of metoclopramide. Am J Proctol Gastroenterol Colon Rectal Surg 32: 12–13, 27–28
Sachdev PS (2005) Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am 28: 255–274
Seeman P (1988) Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J Clin Psychopharmacol 8 (Suppl 4): S3–S9
De Keyser J (1991) Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin Neuropharmacol 14: 562–565
Mitchell IJ et al. (1992) Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the Cebus monkey. Mov Disord 7: 32–37
Auchus AP and Pickel VM (1992) Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: implications for the pathogenesis of neuroleptic-induced movement disorders. Exp Neurol 117: 17–27
Pall HS et al. (1987) Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 2: 596–599
Burkhardt C et al. (1993) Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 33: 512–517
Kerns JM et al. (1992) Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clin Neuropharmacol 15: 488–500
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Pasricha, P., Pehlivanov, N., Sugumar, A. et al. Drug Insight: from disturbed motility to disordered movement—a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Rev Gastroenterol Hepatol 3, 138–148 (2006). https://doi.org/10.1038/ncpgasthep0442
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0442
This article is cited by
-
Metoclopramide-induced acute dystonic reactions: a case report
Journal of Medical Case Reports (2021)
-
Functional syndromes and symptom-orientated aftercare after esophagectomy
Langenbeck's Archives of Surgery (2021)
-
Supportive medication in cancer during pregnancy
BMC Pregnancy and Childbirth (2020)
-
Chronic nausea and vomiting: evaluation and treatment
American Journal of Gastroenterology (2018)
-
Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
European Journal of Clinical Pharmacology (2018)